303 related articles for article (PubMed ID: 31089820)
1. An immunotherapy survivor population: health-related quality of life and toxicity in patients with metastatic melanoma treated with immune checkpoint inhibitors.
O'Reilly A; Hughes P; Mann J; Lai Z; Teh JJ; Mclean E; Edmonds K; Lingard K; Chauhan D; Lynch J; Au L; Ludlow A; Pattison N; Wiseman T; Turajlic S; Gore M; Larkin J; Husson O
Support Care Cancer; 2020 Feb; 28(2):561-570. PubMed ID: 31089820
[TBL] [Abstract][Full Text] [Related]
2. Autoantibodies May Predict Immune-Related Toxicity: Results from a Phase I Study of Intralesional
Da Gama Duarte J; Parakh S; Andrews MC; Woods K; Pasam A; Tutuka C; Ostrouska S; Blackburn JM; Behren A; Cebon J
Front Immunol; 2018; 9():411. PubMed ID: 29552014
[TBL] [Abstract][Full Text] [Related]
3. The survivorship experience for patients with metastatic melanoma on immune checkpoint and BRAF-MEK inhibitors.
Lai-Kwon J; Khoo C; Lo S; Milne D; Mohamed M; Raleigh J; Smith K; Lisy K; Sandhu S; Jefford M
J Cancer Surviv; 2019 Aug; 13(4):503-511. PubMed ID: 31165342
[TBL] [Abstract][Full Text] [Related]
4. Experiences of resuming life after immunotherapy and associated survivorship care needs: a qualitative study among patients with metastatic melanoma.
Kamminga NCW; van der Veldt AAM; Joosen MCW; de Joode K; Joosse A; Grünhagen DJ; Nijsten TEC; Wakkee M; Lugtenberg M
Br J Dermatol; 2022 Sep; 187(3):381-391. PubMed ID: 35596713
[TBL] [Abstract][Full Text] [Related]
5. Health-related quality of life, emotional burden, and neurocognitive function in the first generation of metastatic melanoma survivors treated with pembrolizumab: a longitudinal pilot study.
Rogiers A; Leys C; De Cremer J; Awada G; Schembri A; Theuns P; De Ridder M; Neyns B
Support Care Cancer; 2020 Jul; 28(7):3267-3278. PubMed ID: 31745697
[TBL] [Abstract][Full Text] [Related]
6. Concurrent Immune Checkpoint Inhibitors and Stereotactic Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma.
Chen L; Douglass J; Kleinberg L; Ye X; Marciscano AE; Forde PM; Brahmer J; Lipson E; Sharfman W; Hammers H; Naidoo J; Bettegowda C; Lim M; Redmond KJ
Int J Radiat Oncol Biol Phys; 2018 Mar; 100(4):916-925. PubMed ID: 29485071
[TBL] [Abstract][Full Text] [Related]
7. Neurocognitive Function, Psychosocial Outcome, and Health-Related Quality of Life of the First-Generation Metastatic Melanoma Survivors Treated with Ipilimumab.
Rogiers A; Leys C; Lauwyck J; Schembri A; Awada G; Schwarze JK; De Cremer J; Theuns P; Maruff P; De Ridder M; Bernheim JL; Neyns B
J Immunol Res; 2020; 2020():2192480. PubMed ID: 32775464
[TBL] [Abstract][Full Text] [Related]
8. Health-related quality of life in survivors of advanced melanoma treated with anti-PD1-based immune checkpoint inhibitors.
Looman EL; Cheng PF; Lai-Kwon J; Morgan L; Wakkee M; Dummer R; Dimitriou F
Cancer Med; 2023 Jun; 12(11):12861-12873. PubMed ID: 37119050
[TBL] [Abstract][Full Text] [Related]
9. The clinical value of combination of immune checkpoint inhibitors in cancer patients: A meta-analysis of efficacy and safety.
Wu Y; Shi H; Jiang M; Qiu M; Jia K; Cao T; Shang Y; Shi L; Jiang K; Wu H
Int J Cancer; 2017 Dec; 141(12):2562-2570. PubMed ID: 28833119
[TBL] [Abstract][Full Text] [Related]
10. Persistent immune-related adverse events after cessation of checkpoint inhibitor therapy: Prevalence and impact on patients' health-related quality of life.
Schulz TU; Zierold S; Sachse MM; Pesch G; Tomsitz D; Schilbach K; Kähler KC; French LE; Heinzerling L
Eur J Cancer; 2022 Nov; 176():88-99. PubMed ID: 36198246
[TBL] [Abstract][Full Text] [Related]
11. Clinical Features, Survival, and Burden of Toxicities in Survivors More Than One Year After Lung Cancer Immunotherapy.
Hsu ML; Murray JC; Psoter KJ; Zhang J; Barasa D; Brahmer JR; Ettinger DS; Forde PM; Hann CL; Lam VK; Levy B; Marrone KA; Patel T; Peterson V; Sagorsky S; Turner M; Anagnostou V; Naidoo J; Feliciano JL
Oncologist; 2022 Nov; 27(11):971-981. PubMed ID: 35972337
[TBL] [Abstract][Full Text] [Related]
12. Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial.
Long GV; Atkinson V; Cebon JS; Jameson MB; Fitzharris BM; McNeil CM; Hill AG; Ribas A; Atkins MB; Thompson JA; Hwu WJ; Hodi FS; Menzies AM; Guminski AD; Kefford R; Kong BY; Tamjid B; Srivastava A; Lomax AJ; Islam M; Shu X; Ebbinghaus S; Ibrahim N; Carlino MS
Lancet Oncol; 2017 Sep; 18(9):1202-1210. PubMed ID: 28729151
[TBL] [Abstract][Full Text] [Related]
13. Management of adverse events related to new cancer immunotherapy (immune checkpoint inhibitors).
Bourke JM; O'Sullivan M; Khattak MA
Med J Aust; 2016 Nov; 205(9):418-424. PubMed ID: 27809739
[TBL] [Abstract][Full Text] [Related]
14. Improved Progression-Free Long-Term Survival of a Nation-Wide Patient Population with Metastatic Melanoma.
Soerensen AV; Ellebaek E; Bastholt L; Schmidt H; Donia M; Svane IM
Cancers (Basel); 2020 Sep; 12(9):. PubMed ID: 32932758
[TBL] [Abstract][Full Text] [Related]
15. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
16. Outcomes in Melanoma Patients Treated with BRAF/MEK-Directed Therapy or Immune Checkpoint Inhibition Stratified by Clinical Trial versus Standard of Care.
Goldman C; Tchack J; Robinson EM; Han SW; Moran U; Polsky D; Berman RS; Shapiro RL; Ott PA; Osman I; Zhong H; Pavlick AC; Wilson MA
Oncology; 2017; 93(3):164-176. PubMed ID: 28601879
[TBL] [Abstract][Full Text] [Related]
17. Association of Immunotherapy With Overall Survival in Elderly Patients With Melanoma.
Perier-Muzet M; Gatt E; Péron J; Falandry C; Amini-Adlé M; Thomas L; Dalle S; Boespflug A
JAMA Dermatol; 2018 Jan; 154(1):82-87. PubMed ID: 29214290
[TBL] [Abstract][Full Text] [Related]
18. Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition.
Heppt MV; Heinzerling L; Kähler KC; Forschner A; Kirchberger MC; Loquai C; Meissner M; Meier F; Terheyden P; Schell B; Herbst R; Göppner D; Kiecker F; Rafei-Shamsabadi D; Haferkamp S; Huber MA; Utikal J; Ziemer M; Bumeder I; Pfeiffer C; Schäd SG; Schmid-Tannwald C; Tietze JK; Eigentler TK; Berking C
Eur J Cancer; 2017 Sep; 82():56-65. PubMed ID: 28648699
[TBL] [Abstract][Full Text] [Related]
19. Revisiting the association between skin toxicity and better response in advanced cancer patients treated with immune checkpoint inhibitors.
Gulati N; Donnelly D; Qian Y; Moran U; Johannet P; Zhong J; Osman I
J Transl Med; 2020 Nov; 18(1):430. PubMed ID: 33176813
[TBL] [Abstract][Full Text] [Related]
20. Response of metastatic mucosal melanoma to immunotherapy: It can get worse before it gets better.
Atrash S; Makhoul I; Mizell JS; Hutchins L; Mahmoud F
J Oncol Pharm Pract; 2017 Apr; 23(3):215-219. PubMed ID: 26811403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
